Payment overview · 2025
General Payments
$1,982.51
133 reported records · 24 companies
Healthcare provider profile · identity verified
Chad Wade Mcelroy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOULTON, AL · NPI 1154472355
Verified facts
What the public records show
CMS Open Payments records show Chad Wade Mcelroy, M.D. received $1,982.51 in general payments during 2025 across 133 reported records.
Paratek Pharmaceuticals, Inc. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Ozempic, Rexulti, Rybelsus, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $310.93 | 15.7% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $305.36 | 15.4% | 28 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $167.52 | 8.4% | 28 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.67 | 6.8% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $116.33 | 5.9% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.10 | 5.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.91 | 5.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.52 | 4.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $92.51 | 4.7% | 4 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $87.25 | 4.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.53 | 2.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.42 | 2.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.18 | 2.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.06 | 2.4% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $42.93 | 2.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $32.66 | 1.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.44 | 1.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.86 | 1.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.74 | 1.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.98 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.69 | 1.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.26 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.50 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.16 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,966.24 | 132 |
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $310.93 | 20 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $167.52 | 28 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $154.37 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.99 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $148.38 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $118.92 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $116.33 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $112.10 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $104.91 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $92.51 | 4 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $87.25 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $78.51 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.79 | 3 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $74.55 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.03 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.56 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $52.42 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.18 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $42.93 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.24 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 568 | 163 |
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 113 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 389 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 385 | 61 |
| Omeprazole | Omeprazole | 368 | 98 |
| Tramadol Hcl | Tramadol Hcl | 358 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 83 |
| Lisinopril | Lisinopril | 291 | 88 |
| Pregabalin | Pregabalin | 243 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 227 | 57 |
| Furosemide | Furosemide | 220 | 69 |
| Gabapentin | Gabapentin | 218 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 59 |
| Mounjaro | Tirzepatide | 202 | 34 |
| Potassium Chloride | Potassium Chloride | 196 | 56 |
| Montelukast Sodium | Montelukast Sodium | 190 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 188 | 22 |
| Temazepam | Temazepam | 188 | 24 |
| Meloxicam | Meloxicam | 171 | 50 |
| Valsartan | Valsartan | 167 | 47 |
| Metformin Hcl Er | Metformin Hcl | 162 | 55 |
| Lorazepam | Lorazepam | 159 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 38 |
| Methocarbamol | Methocarbamol | 148 | 41 |
| Trazodone Hcl | Trazodone Hcl | 147 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 40 |
| Metformin Hcl | Metformin Hcl | 139 | 39 |
| Methylprednisolone | Methylprednisolone | 135 | 96 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 130 | 30 |
| Ozempic | Semaglutide | 118 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 31 |
| Celecoxib | Celecoxib | 115 | 32 |
| Clonazepam | Clonazepam | 114 | 21 |
| Memantine Hcl | Memantine Hcl | 110 | 23 |
| Simvastatin | Simvastatin | 110 | 35 |
| Sertraline Hcl | Sertraline Hcl | 106 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 26 |
| Farxiga | Dapagliflozin Propanediol | 100 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 29 |
| Jardiance | Empagliflozin | 98 | 20 |
| Buspirone Hcl | Buspirone Hcl | 96 | 29 |
| Alendronate Sodium | Alendronate Sodium | 94 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 22 |
| Losartan Potassium | Losartan Potassium | 91 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 37 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 85 | 23 |
| Eliquis | Apixaban | 84 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 74 | 18 |
| Diazepam | Diazepam | 73 | 11 |
| Ezetimibe | Ezetimibe | 72 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 18 |
| Trulicity | Dulaglutide | 67 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 20 |
| Prednisone | Prednisone | 62 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 17 |
| Eszopiclone | Eszopiclone | 61 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 19 |
| Glipizide | Glipizide | 58 | 14 |
| Allopurinol | Allopurinol | 57 | 21 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Fenofibrate | Fenofibrate | 56 | 13 |
| Mupirocin | Mupirocin | 56 | 42 |
| Glimepiride | Glimepiride | 54 | 15 |
| Topiramate | Topiramate | 54 | 12 |
| Cephalexin | Cephalexin | 53 | 35 |
| Azithromycin | Azithromycin | 52 | 46 |
| Bumetanide | Bumetanide | 51 | 17 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | 16 |
| Nabumetone | Nabumetone | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 40 |
| Estradiol | Estradiol | 49 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 42 |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | 15 |
| Sucralfate | Sucralfate | 46 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 15 |
| Febuxostat | Febuxostat | 44 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 24 |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Carvedilol | Carvedilol | 42 | 15 |
| Levofloxacin | Levofloxacin | 42 | 34 |
| Promethazine Hcl | Promethazine Hcl | 42 | 11 |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 28 |
| Spironolactone | Spironolactone | 38 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 35 | suppressed |
| Vraylar | Cariprazine Hcl | 35 | suppressed |
| Finasteride | Finasteride | 34 | 12 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 17 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Nystatin | Nystatin | 28 | 17 |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 16 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Trulance | Plecanatide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,982.51 · 133 records | Paratek Pharmaceuticals, Inc. | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, INSPIRE, JARDIANCE, JATENZO, JOURNAVX, Kerendia, Korlym, LEQVIO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, XHANCE, XYOSTED, ZAVZPRET, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error